# Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

> **NCT01797445** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 872 (actual)

## Conditions studied

- HIV
- HIV Infections

## Interventions

- **DRUG:** E/C/F/TAF
- **DRUG:** E/C/F/TDF
- **DRUG:** E/C/F/TDF Placebo
- **DRUG:** E/C/F/TAF Placebo

## Key facts

- **NCT ID:** NCT01797445
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-12
- **Primary completion:** 2014-09-19
- **Final completion:** 2018-10-03
- **Target enrollment:** 872 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01797445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01797445, "Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01797445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*